Loading...
Loading...
XOMA Corporation
XOMA today announced its partner, Servier has received authorization
to initiate the Servier-sponsored Behçet's uveitis Phase 3 clinical trial in
several European countries. The study is titled A randomisEd, double-masked,
placebo-controlled studY of the Efficacy of GevokizUmAb in the tReatment of
patients with Behçet's Disease uveitis (EYEGUARD™-B). The objective of this
study is to evaluate the efficacy of gevokizumab as compared to placebo on top
of current standard of care (immunosuppressive therapy and oral
corticosteroids) in reducing the risk of Behçet's disease uveitis
exacerbations and to assess the safety of gevokizumab.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in